Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
March 20, 2024 08:30 ET
|
Silo Pharma, Inc.
Exclusive license for development, manufacturing, and commercialization in process Silo Pharma to file Pre-IND in first half 2024 SARASOTA, FL, March 20, 2024 (GLOBE NEWSWIRE) -- Silo Pharma,...
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
March 18, 2024 07:15 ET
|
Silo Pharma, Inc.
Silo reports positive stability of SP-26 for time-release and dosage control SARASOTA, FL, March 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a...
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
February 28, 2024 08:25 ET
|
Silo Pharma, Inc.
All animal subjects tolerated maximum dosing Once-per-day human intranasal dosing regimen determined for clinical evaluation SARASOTA, FL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc....
Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
February 14, 2024 08:45 ET
|
Silo Pharma, Inc.
Initial indications target fibromyalgia and chronic pain Loaded and encapsulated drug maintains structural stability as implantable treatment SARASOTA, FL, Feb. 14, 2024 (GLOBE NEWSWIRE)...
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
February 01, 2024 10:00 ET
|
Silo Pharma, Inc.
Preparing Pre-Investigational New Drug Application for lead drug program SPC-15 Company plans to pursue FDA streamlined 505(b)(2) pathway for clinical drug development SARASOTA, FL, Feb. 01,...
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
January 24, 2024 08:55 ET
|
Silo Pharma, Inc.
Preclinical study shows SPC-14’s effectiveness against LH (luteinizing hormone) stress, helplessness, and anxiety. SARASOTA, FL, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO)...
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
January 04, 2024 08:55 ET
|
Silo Pharma, Inc.
Final validation report expected in first quarter 2024 ENGLEWOOD CLIFFS, NJ, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage...
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
December 28, 2023 08:25 ET
|
Silo Pharma, Inc.
Silo dosage and time-release formulation aim for potential first at-home Ketamine therapeutic SARASOTA, FL, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the...
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
November 21, 2023 08:01 ET
|
Silo Pharma, Inc.
MedSpray’s patented nose-to-brain intranasal technology selected for SPC-15 drug delivery Exclusivity covers multiple indications including anxiety disorders, Alzheimer’s disease, and anorexia ...
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
November 08, 2023 08:11 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...